27th August, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 of the Listing Regulations, we hereby inform you that with a view to rationalise and simplify the group structure, Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake).

Consequently, Aspergen Inc., USA has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA pursuant to the aforesaid restructuring.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 on the captioned subject are enclosed to this letter.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.08.27 20:08:08 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Simona Dsouza

Cipla

Annexure - I

Details as per SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026

<table>
<tr><th>Sr. No.</th><th>Particulars</th><th>Details</th></tr>
<tr><td>a)</td><td>details and reasons for restructuring</td><td rowspan="2">Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring.

The said restructuring has been undertaken with a view to rationalise and simplify the group structure.</td></tr>
<tr><td>b)</td><td>quantitative and/ or qualitative effect of restructuring</td></tr>
<tr><td>c)</td><td>details of benefit, if any, to the promoter/promoter group / group companies from such proposed restructuring</td><td>Nil</td></tr>
<tr><td>d)</td><td>brief details of change in shareholding pattern (if any) of all entities</td><td>Change in shareholding pattern:
<table>
<tr><th rowspan="2">Name of Company</th><th colspan="2">Pre-restructuring</th><th colspan="2">Post-restructuring</th></tr>
<tr><th>Name of shareholders</th><th>Stake held</th><th>Name of shareholders</th><th>Stake held</th></tr>
<tr><td rowspan="2">Aspergen Limited, India</td><td>Cipla Limited</td><td>60%</td><td>Cipla Limited</td><td>60%</td></tr>
<tr><td>Kemwell Biopharma Private Limited</td><td>40%</td><td>Kemwell Biopharma Private Limited</td><td>40%</td></tr>
<tr><td rowspan="2">Aspergen Inc., USA</td><td>Cipla (EU) Limited</td><td>60%</td><td rowspan="2">Aspergen Limited</td><td rowspan="2">100%</td></tr>
<tr><td>Kemwell Biopharma UK Limited</td><td>40%</td></tr>
</table>
There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring.</td></tr>
</table>

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 **W** www.cipla.com **E-mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380